T3 Pharma closes first financing round to advance research and preclinical development of breakthrough bacteria-based cancer therapies

 T3 Pharmaceuticals Ltd (“T3 Pharma”), a Swiss-based biotechnology company specializing in breakthrough bacteria–based cancer therapies, today announced the successful closing of its first financing round. The funding has been provided by private Swiss investors and will secure further growth of the company, in particular the expansion of research activities and the initiation of preclinical development.

The financing round complements the successful efforts raising significant non-dilutive capital from the Swiss Commission for Technology and Innovation and various research foundations. T3 Pharma is a spin-off from the Biozentrum of the University of Basel. The Company focuses on novel therapies for cancer patients. T3 Pharma has been engineering live bacteria to specifically infect solid tumors and fighting them with a proprietary protein delivery technology developed at the University of Basel.

“Our strong investor base and the support by the University of Basel provide perfect conditions for the development of our breakthrough technology in cancer therapies”, said Dr. Simon Ittig, CEO and  co-founder of T3 Pharma. “This first financing round allows us to advance initial lead candidates into preclinical development.”

“It belongs to the mission of a modern University to help translating basic research into tangible benefits for patients and society,” explained Prof. Dr. Erich Nigg, Director of the Biozentrum. “We hope that T3 Pharma can exploit their innovative platform to bring novel treatments to cancer patients.”